{
    "organizations": [],
    "uuid": "0a37ececfe2db0e51d24b8be6e872913b0af925f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-diasorin-earns-fda-clearance-exten/brief-diasorin-earns-fda-clearance-extending-sample-claims-for-hsv-1-2-test-idUSFWN1RA0O8",
    "ord_in_thread": 0,
    "title": "BRIEF-DiaSorin Earns FDA Clearance Extending Sample Claims For HSV 1 & 2 Test",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - DIASORIN SPA:\n* EARNS FDA CLEARANCE EXTENDING SAMPLE CLAIMS FOR SIMPLEXA HSV 1 & 2 DIRECT MOLECULAR TEST\n* EXTENSION ADDS CUTANEOUS AND MUCOCUTANEOUS LESION SWABS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-28T22:51:00.000+03:00",
    "crawled": "2018-03-29T15:37:15.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "diasorin",
        "spa",
        "earns",
        "fda",
        "clearance",
        "extending",
        "sample",
        "claim",
        "simplexa",
        "hsv",
        "direct",
        "molecular",
        "test",
        "extension",
        "add",
        "cutaneous",
        "mucocutaneous",
        "lesion",
        "swab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}